ADA and pulmonary fibrosis: Genetic loss of CD73 or pharmacological inhibition with a CD73-antibody or by degradation of adenosine with pegylated-adenosine deaminase (PEG-ADA) significantly reduced levels of pro-fibrotic mediators and attenuated the extent of pulmonary fibrosis.